Controversies in NSCLC: which second-line strategy after chemo-immunotherapy?

por Moliner, L., Spurgeon, L., Califano, R.
Publicado 2023

First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions

por Ortega-Franco, A., Ackermann, C., Paz-Ares, L., Califano, R.
Publicado 2021

Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer

por Baka, S, Califano, R, Ferraldeschi, R, Aschroft, L, Thatcher, N, Taylor, P, Faivre-Finn, C, Blackhall, F, Lorigan, P
Publicado 2008

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer

por Haslett, K., Koh, P., Hudson, A., Ryder, W.D., Falk, S., Mullan, D., Taylor, B., Califano, R., Blackhall, F., Faivre-Finn, C.
Publicado 2021

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK

por Califano, R., Tariq, N., Compton, S., Fitzgerald, D. A., Harwood, C. A., Lal, R., Lester, J., McPhelim, J., Mulatero, C., Subramanian, S., Thomas, A., Thatcher, N., Nicolson, M.
Publicado 2015

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours

por Khan, O A, Gore, M, Lorigan, P, Stone, J, Greystoke, A, Burke, W, Carmichael, J, Watson, A J, McGown, G, Thorncroft, M, Margison, G P, Califano, R, Larkin, J, Wellman, S, Middleton, M R
Publicado 2011

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report

por Hardenberg, M.C., Patel, B., Matthews, C., Califano, R., Garcia Campelo, R., Grohe, C., Hong, M.H., Liu, G., Lu, S., de Marinis, F., Pérol, M., Soo, R.A., Stiles, B.M., Tiseo, M., Tsuboi, M.
Publicado 2022